Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.

Siljehult F, Ärlestig L, Eriksson C, Rantapää-Dahlqvist S.

Scand J Rheumatol. 2018 Apr 27:1-6. doi: 10.1080/03009742.2018.1433232. [Epub ahead of print]

PMID:
29701536
2.

Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis.

Leonard D, Svenungsson E, Dahlqvist J, Alexsson A, Ärlestig L, Taylor KE, Sandling JK, Bengtsson C, Frodlund M, Jönsen A, Eketjäll S, Jensen-Urstad K, Gunnarsson I, Sjöwall C, Bengtsson AA, Eloranta ML, Syvänen AC, Rantapää-Dahlqvist S, Criswell LA, Rönnblom L.

Ann Rheum Dis. 2018 Jul;77(7):1063-1069. doi: 10.1136/annrheumdis-2017-212614. Epub 2018 Mar 7.

3.

An increased concentration of receptor activator of nuclear factor kappa-B ligand pre-dates the onset of rheumatoid arthritis.

Johansson L, Ärlestig L, Kokkonen H, Brink M, Rantapää-Dahlqvist S.

Rheumatology (Oxford). 2017 Dec 1;56(12):2190-2196. doi: 10.1093/rheumatology/kex339.

PMID:
29029341
4.

Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis.

Boman A, Kokkonen H, Ärlestig L, Berglin E, Rantapää-Dahlqvist S.

Clin Rheumatol. 2017 May;36(5):1005-1012. doi: 10.1007/s10067-017-3570-4. Epub 2017 Feb 11.

5.

Metabolite and Lipid Profiling of Biobank Plasma Samples Collected Prior to Onset of Rheumatoid Arthritis.

Surowiec I, Ärlestig L, Rantapää-Dahlqvist S, Trygg J.

PLoS One. 2016 Oct 18;11(10):e0164196. doi: 10.1371/journal.pone.0164196. eCollection 2016.

6.

Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis.

Johansson L, Pratesi F, Brink M, Ärlestig L, D'Amato C, Bartaloni D, Migliorini P, Rantapää-Dahlqvist S.

Arthritis Res Ther. 2016 Jun 3;18(1):127. doi: 10.1186/s13075-016-1031-0.

7.

An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis.

Jiang X, Källberg H, Chen Z, Ärlestig L, Rantapää-Dahlqvist S, Davila S, Klareskog L, Padyukov L, Alfredsson L.

Rheumatology (Oxford). 2016 Jan;55(1):149-55. doi: 10.1093/rheumatology/kev285. Epub 2015 Aug 13.

PMID:
26272072
8.

Genetic Variants of the NLRP3 Inflammasome Are Associated with Stroke in Patients with Rheumatoid Arthritis.

Kastbom A, Ärlestig L, Rantapää-Dahlqvist S.

J Rheumatol. 2015 Oct;42(10):1740-5. doi: 10.3899/jrheum.141529. Epub 2015 Jul 15.

PMID:
26178285
9.

Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes.

Franke L, el Bannoudi H, Jansen DT, Kok K, Trynka G, Diogo D, Swertz M, Fransen K, Knevel R, Gutierrez-Achury J, Ärlestig L, Greenberg JD, Kremer J, Pappas DA, Kanterakis A, Weersma RK, van der Helm-van Mil AH, Guryev V, Rantapää-Dahlqvist S, Gregersen PK, Plenge RM, Wijmenga C, Huizinga TW, Ioan-Facsinay A, Toes RE, Zhernakova A.

Eur J Hum Genet. 2016 Feb;24(2):263-70. doi: 10.1038/ejhg.2015.95. Epub 2015 May 13.

10.

High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci.

Kim K, Bang SY, Lee HS, Cho SK, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Kang YM, Kim SK, Suh CH, Shim SC, Lee SS, Lee J, Chung WT, Choe JY, Shin HD, Lee JY, Han BG, Nath SK, Eyre S, Bowes J, Pappas DA, Kremer JM, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlestig L, Okada Y, Diogo D, Liao KP, Karlson EW, Raychaudhuri S, Rantapää-Dahlqvist S, Martin J, Klareskog L, Padyukov L, Gregersen PK, Worthington J, Greenberg JD, Plenge RM, Bae SC.

Ann Rheum Dis. 2015 Mar;74(3):e13. doi: 10.1136/annrheumdis-2013-204749. Epub 2014 Feb 14.

11.

Genetics of rheumatoid arthritis contributes to biology and drug discovery.

Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Bridges SL Jr, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop M; RACI consortium; GARNET consortium, Eyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM.

Nature. 2014 Feb 20;506(7488):376-81. doi: 10.1038/nature12873. Epub 2013 Dec 25.

12.

Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeans.

Cobb JE, Plant D, Flynn E, Tadjeddine M, Dieudé P, Cornélis F, Ärlestig L, Dahlqvist SR, Goulielmos G, Boumpas DT, Sidiropoulos P, Krintel SB, Ørnbjerg LM, Hetland ML, Klareskog L, Haeupl T, Filer A, Buckley CD, Raza K, Witte T, Schmidt RE, FitzGerald O, Veale D, Eyre S, Worthington J.

PLoS One. 2013 Jun 20;8(6):e66456. doi: 10.1371/journal.pone.0066456. Print 2013.

13.

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study.

Kastbom A, Cöster L, Arlestig L, Chatzidionysiou A, van Vollenhoven RF, Padyukov L, Rantapää-Dahlqvist S, Saevarsdottir S.

BMJ Open. 2012 Sep 22;2(5). pii: e001524. doi: 10.1136/bmjopen-2012-001524. Print 2012.

14.

Polymorphisms of the genes encoding CD40 and growth differentiation factor 15 and in the 9p21.3 region in patients with rheumatoid arthritis and cardiovascular disease.

Ärlestig L, Rantapää-Dahlqvist S.

J Rheumatol. 2012 May;39(5):939-45. doi: 10.3899/jrheum.111336. Epub 2012 Apr 15.

15.

Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden.

Ärlestig L, Mullazehi M, Kokkonen H, Rocklöv J, Rönnelid J, Dahlqvist SR.

Ann Rheum Dis. 2012 Jun;71(6):825-9. doi: 10.1136/annrheumdis-2011-200668. Epub 2011 Nov 29.

16.

Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers.

Plant D, Flynn E, Mbarek H, Dieudé P, Cornelis F, Arlestig L, Dahlqvist SR, Goulielmos G, Boumpas DT, Sidiropoulos P, Johansen JS, Ørnbjerg LM, Hetland ML, Klareskog L, Filer A, Buckley CD, Raza K, Witte T, Schmidt RE, Worthington J.

Ann Rheum Dis. 2010 Aug;69(8):1548-53. doi: 10.1136/ard.2009.121020. Epub 2010 May 24.

17.

Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis.

Arlestig L, Wållberg Jonsson S, Stegmayr B, Rantapää-Dahlqvist S.

Clin Exp Rheumatol. 2007 Nov-Dec;25(6):866-71.

PMID:
18173921
18.

Genetic variations in the serotonin 5-HT2A receptor gene (HTR2A) are associated with rheumatoid arthritis.

Kling A, Seddighzadeh M, Arlestig L, Alfredsson L, Rantapää-Dahlqvist S, Padyukov L.

Ann Rheum Dis. 2008 Aug;67(8):1111-5. Epub 2007 Nov 15.

PMID:
18006541
20.

Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus.

Johansson M, Arlestig L, Möller B, Rantapää-Dahlqvist S.

Arthritis Rheum. 2005 Jun;52(6):1665-9.

21.

Oestrogen receptor {alpha} gene polymorphisms in systemic lupus erythematosus.

Johansson M, Arlestig L, Möller B, Smedby T, Rantapää-Dahlqvist S.

Ann Rheum Dis. 2005 Nov;64(11):1611-7. Epub 2005 Apr 7.

22.

Monoclonal antibodies against tissue-nonspecific alkaline phosphatase. Report of the ISOBM TD9 workshop.

Magnusson P, Arlestig L, Paus E, Di Mauro S, Testa MP, Stigbrand T, Farley JR, Nustad K, Millán JL.

Tumour Biol. 2002 Jul-Aug;23(4):228-48.

PMID:
12499779
24.

Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop.

Stigbrand T, Andrés C, Bellanger L, Bishr Omary M, Bodenmüller H, Bonfrer H, Brundell J, Einarsson R, Erlandsson A, Johansson A, Leca JF, Levi M, Meier T, Nap M, Nustad K, Seguin P, Sjödin A, Sundström B, van Dalen A, Wiebelhaus E, Wiklund B, Arlestig L, Hilgers J.

Tumour Biol. 1998;19(2):132-52.

PMID:
9486565
25.

Endogenous anti-tumor antibody responses in nude mice.

Stigbrand T, Ullén A, Sandström P, Rathsman S, Rossi Norrlund R, Arlestig L, Riklund Ahlström K, Hietala SO.

Cancer. 1997 Dec 15;80(12 Suppl):2404-10.

PMID:
9406690
26.

Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy.

Ullén A, Ahlström KR, Heitala S, Nilsson B, Arlestig L, Stigbrand T.

Acta Oncol. 1996;35(3):281-5. Review.

PMID:
8679257
27.

Twenty years with monoclonal antibodies: State of the art--Where do we go?

Stigbrand T, Ullén A, Sandstrom P, Mirzaie-Joniani H, Sundström B, Nillson B, Arlestig L, Norrlund RR, Ahlström KR, Hietala S.

Acta Oncol. 1996;35(3):259-65. Review.

PMID:
8679254
28.

Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:nontumor ratio in experimental radioimmunolocalization.

Ullén A, Sandström P, Ahlström KR, Sundström B, Nilsson B, Arlestig L, Stigbrand T.

Cancer Res. 1995 Dec 1;55(23 Suppl):5868s-5873s.

Supplemental Content

Loading ...
Support Center